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ABSTRACT 
Neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease and 
Amyotrophic Lateral Sclerosis are marked by the loss of different types of 
neurons and glial cells in the central nervous system (CNS). Human Pluripotent 
Stem Cell (hPSC)-derived Neural Progenitor Cells (hNPCs) have the ability to self-
renew indefinitely and to differentiate into various cell types of the CNS. HNPCs 
can be used in cell based therapies and have the potential to reverse or arrest 
neurodegeneration and to replace lost neurons and glial cells. However, the lack 
of completely defined, scalable systems to culture these cells, limits their 
therapeutic and clinical applications. In a previous study, a completely defined, 
robust, synthetic peptide- a Vitronectin Derived Peptide (VDP) that supports the 
long term expansion and differentiation of various embryonic and induced 
pluripotent stem cell (hESC/hIPSC) derived hNPC lines on two dimensional (2D) 
tissue culture plates was identified. In this study, the culture of hNPCs was scaled 
up using VDP coated microcarriers (MC). VDP MC were able to support the long 
term expansion of hESC and hiPSC derived hNPCs over multiple passages and 
supported higher fold changes in cell densities, compared to VDP coated 2D 
surfaces. VDP MC also showed the ability to support the neuronal differentiation 
of hNPCs, and produced mature neurons expressing several neuronal, 
neurotransmitter and cortical markers. Additionally, alzheimer’s disease (AD) 
relevant phenotypes were studied in patient hIPSC derived hNPCs cultured on 
laminin MC to assess if the MC culture system could be used for disease 
modelling and drug screening. Finally, a microcarrier based bioreactor system 
was developed for the large scale expansion of hNPCs, exhibiting more than a 
five-fold change in cell density and supporting more than 100 million hNPCs in 
culture. Thus, the development of a xeno-free, scalable system allows hNPC 
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culture under standard and reproducible conditions in quantities required for 
therapeutic and clinical applications. 
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1. Introduction 
1.1 Neurodegenerative Diseases and Stem Cells 
Neurodegenerative diseases are one of the leading causes of death in the United 
States and are caused by the loss of different types of neurons and glial cells in 
the central nervous system. For instance, Parkinson’s Disease is caused by the 
loss of mid-brain dopaminergic neurons, while Alzheimer’s Disease is marked by 
the loss of forebrain cholinergic neurons and Amyotrophic Lateral Sclerosis is 
caused by the degeneration of motor neurons in the spinal cord and in the 
cerebral cortex (Lindvall & Kokaia, 2006). Additionally, conditions such as stroke, 
cause vascular damage resulting in ischaemia, thereby leading to neuronal and 
glial cell death. Current treatment methods for such diseases are only palliative 
and in case of diseases such as Amyotrophic Lateral Sclerosis, no effective 
treatment exists. Moreover, the mechanisms of these diseases are poorly 
understood due to the lack of models that faithfully recapitulate their pathologies. 
Generally animal models, such as the triple transgenic model for AD or post-
mortem tissue are used to probe these diseases. However, animal models do not 
exhibit all the pathologies of the disease and post-mortem studies depict a 
terminal stage picture of the disease rather than its progression. Stem cell based 
therapies are a promising method of treatment for neurodegenerative disorders 
due to the ability of stem cells to self-renew indefinitely and to differentiate into 
the required cell types to replenish the lost neurons or glia. 
Neural Progenitor Cells and potential applications 
Stem cells with the ability to differentiate into various cell types of all three germ 
layers are called pluripotent stem cells and the stem cells whose fate is rather 
restricted, and can therefore, differentiate into only certain specific cell types are 
called adult stem cells. 
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Pluripotent stem cells derived from the inner cell mass of blastocysts are termed 
Embryonic Stem Cells (ESC). The ethical concerns surrounding ESCs limits their 
use on a wide scale. However, the ability to derive pluripotent stem cells (termed 
human induced pluripotent stem cells or hiPSCs) by reprogramming somatic cells 
by overexpressing certain transcription factors - cMyc, Oct4, Sox2, Klf4 
(Takahashi et al., 2007) has introduced the possibility of using hPSCs and their 
derivatives for clinical applications. Moreover, patient specific hiPSCs could lend 
valuable insights into the mechanisms and progression of sporadic forms of 
certain diseases, not easily modelled by any other means. However, the ability of 
hPSCs to differentiate into cells of all three germ layers poses a risk of 
tumorigenicity, which is why in this study, we focused on expanding a multipotent 
progenitor population, called neural progenitor cells (hNPCs), capable of further 
differentiating into various cell types of the central nervous system, such as 
neurons, astrocytes and oligodendrocytes making them better suited for clinical 
applications related to neurodegenerative diseases. 
Neural Progenitor Cells are derived from pluripotent stem cells by forcing 
ESCs/iPSCs down the neuroectodermal differentiation pathway. First, hPSCs are 
forced to form aggregates known as Embryoid Bodies in low adhesion plates and 
are cultured in neural induction media for 5 days, after which they are dissociated 
and plated on Matrigel™ to form neural rosettes. The rosettes are cultured in 
neural induction media for 7 days, after which they are dissected and plated on 
PLO/Ln coated tissue culture plates to form hNPCs. These hNPCs are cultured in 
neural expansion media with EGF and FGF and express markers such as SOX1, 
SOX2 and Nestin. HNPCs can be further differentiated into neurons by switching 
to neural differentiation media with BDNF and GDNF (Brafman, 2015). 
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Figure 1-1: Protocol for differentiating hPSCs into hNPCs. (Brafman, 2015) 
Studies suggest that hNPCs can be used in cell based therapies and have the 
potential to reverse or arrest neurodegeneration and to replace lost neurons and 
glial cells (Schwartz et al., 2012; Lindvall & Kokaia, 2006). For instance, grafting 
hNPCs in rats with T3 spinal cord injury showed long distance axonal growth 
across the injury site (Lu et al., 2012). Patient-specific iPSC derived hNPCs have 
also been used to model neurodegenerative diseases such as AD (Israel et al., 
2012) and to facilitate drug discovery for diseases such as ALS (Egawa et al., 
2012). 
1.2 Bottlenecks in Cell Based Therapies 
While stem cell derived hNPCs can potentially be used for therapeutic purposes, 
their clinical application is limited by a number of factors, including scalability and 
lack of xeno-free, defined culture conditions. HNPCs are typically cultured on 2-D 
tissue culture plates coated with laminin (Ln) or Matrigel™, which are animal 
derived ECMP based substrates. These substrates are expensive, subject to lot-
to-lot variations and contain chemically undefined and potentially harmful 
xenogeneic components, thereby making hNPCs cultured on them unsuitable for 
clinical applications. 
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The cell numbers required for clinical applications far exceed the numbers 
typically obtained by conventional 2-D culture methods, where the surface area 
available for cell growth is limited and the culture cannot be easily scaled up. 
Moreover, monolayer culture does not resemble the cell’s in vivo 
microenvironment. 
1.3 Synthetic substrates 
To replace the use of animal derived ECMP substrates, several chemically defined 
synthetic substrates have been developed for culturing cells. These can be 
broadly classified as synthetic polymers and synthetic peptides. Several polymers 
have been shown to support the growth of hPSCs (Celiz et al., 2014) and hNPCs 
(Tsai et al., 2015). These substrates are economical and allow cell growth under 
reproducible conditions. However, the preparation of such polymer coated 
surfaces requires complex fabrication methods which limits their use on a wider 
scale. Synthetic peptides such as Vitronectin Derived Peptide used in this study, 
on the other hand, are short amino acid sequences that can often be simply 
coated on tissue culture treated plates, making them easier to use. 
1.3.1 Identification of Vitronectin Derived Peptide as a synthetic peptide-based 
substrate for hNPC culture 
Cells are surrounded by a complex network of proteins and polysaccharides 
known as the extracellular matrix. Extracellular matrix proteins such as laminin, 
vitronectin and fibronectin, not only facilitate cell adhesion, but also control cell 
fate by influencing signalling pathways through a network of cell surface 
receptors known as integrins. Integrins are transmembrane proteins composed of 
α and β sub-units that bind to ECMPs on the extracellular domain and to 
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cytoskeletal elements on the intracellular domain. There are 18 α sub units and 8 
β sub units and these form dimers in specific combinations according to the 
ECMPs in the cell’s microenvironment. For instance, α6β1 binds to laminin, α5β1 
binds to fibronectin and αvβ5 binds to fibronectin and vitronectin. Although ECMPs 
are complex and consist of numerous receptor binding domains, integrins can 
interact with certain cell binding domains of ECMPs to facilitate cell adhesion and 
growth. Thus, synthetic peptides consisting of short sequences, derived from the 
cell binding domains of ECMPS such as laminin, fibronectin and vitronectin can be 
used to culture cells instead of undefined ECMP substrates.  
 
Figure 1-2: Integrin- ECMP interaction regulates stem cell fate. Integrins 
are transmembrane proteins that have an extracellular domain that interacts with 
ECMPs such as laminin, vitronectin, fibronectin etc. and a cytoplasmic domain 
that regulates cytoskeletal elements and affects signalling based on their 
interaction with ECMPs to decide cell fate. (Prowse, Chong, Gray & Munro, 2011) 
To identify such a synthetic peptide-based substrate for hNPC culture, the ECMP 
and integrin expression of hPSC, hNPC and hPSC derived endoderm, mesoderm 
and ectoderm was assessed by performing qPCR and flow cytometry. Flow 
cytometry analysis revealed higher levels of expression of integrin subunits α5, 
α6, αv, β1 and β2, lower levels of expression of α1, α2, α3 and β5 and no expression 
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of α4, β3, β4 and  β7 in hNPCs (Figure 1-3). Using the knowledge of possible 
combinations of integrin subunits that form dimers and the ECMPS they bind to, a 
library of 18 peptides with sequences mimicking ECMPS or those that interact 
with these integrins was made. The adhesion and short term growth of hNPCs on 
these peptides was assessed by seeding hNPCs on 96 well plates coated with 
500μm of these peptides, with hNPCs cultured on laminin as control. Of these 
peptides, four were identified to support cell adhesion and short term growth 
(Figure 1-4).  
 
Figure 1-3: Integrin expression in hNPCs Flow cytometry analysis of integrin 
α1-6,v and β1-5,7 expression in hNPCs. (Varun et al., 2017) 
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Figure 1-4: Identification of peptide-based substrate for hNPC culture. 
(A) Representative phase contrast images on H9 hNPCs cultured on laminin or on 
peptide coated tissue culture surfaces for 72 hours. All peptides were used at a 
concentration of 500μm. (B) Cell counts of H9 hNPCs cultured on laminin or on 
peptide coated tissue culture surfaces for 72 hours. Cell counts were normalized 
to those on laminin surfaces (mean ± s.e.m). Cell counts on peptides were 
compared to those on laminin using Student’s t-test with Bonferroni correction 
(*p<0.05). (Varun et al., 2017) 
Next, the ability of these four peptides to support long term expansion of hNPCs 
was assessed by culturing these cells on the peptides for multiple passages. 
Within 3 to 4 passages, hNPCs started acquiring a differentiated, neuronal 
morphology on 3 of the peptides and only one peptide (peptide 13) was identified 
as a substrate allowing long term expansion of hNPCs (Figure 1-4). This peptide, 
derived from the cell binding domain of Vitronectin (Vogel et al., 1993), and 
therefore, referred to as Vitronectin-Derived Peptide was subsequently used for 
culturing various ESC and iPSC derived hNPC lines such as HES-3, H9, HSF4 and 
NDC. VDP coated tissue culture plates (2D) supported the long term expansion of 
these hNPCs at levels similar to that on laminin (used as control) for more than 
10 passages (Figure 1-5 A and B). HNPCs cultured on VDP showed similar 
doubling times as those cultured on laminin and showed no significant difference 
in the expression of genes such as SOX1, SOX2 and Nestin across multiple 
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passages when cultured on VDP and on laminin (Figure 1-5 D). Flow cytometry 
and immunofluorescence on cells cultured for more than 10 passages on VDP and 
laminin also revealed the presence of a high percentage (>85%) of SOX1, SOX2 
and Nestin positive cells (Figure 1-5 E and F) indicating that VDP could support 
the expansion of hNPCs on levels similar to conventional extracellular matrix 
protein based substrates. 
 
Figure 1-5: Long-term expansion of hNPCs on VDP-coated surfaces. (A) 
Representative phase contrast images of H9-hNPCs cultured on LN and VDP 
surfaces for 10 passages (scale bar = 500 μm). (B) Doubling time of H9-hNPCs 
cultured on LN and VDP. Data is presented as the mean ± S.D of the doubling 
time over the course of 10 passages. There was no statistical difference in the 
doubling time of hNPCs grown on LN and VDP (Student’s t-test, p > 0.05) (C) H9-
hNPCs were cultured on LN and VDP and cell growth was analysed by cell count 
at each passage (mean ± S.E.M). (D) Quantitative PCR analysis for expression of 
hNPC multipotency markers SOX1, SOX2, and NESTIN in H9-hNPCs cultured on 
LN and VDP for 1, 5, and 10 passages (mean ± S.E.M). Two-way analysis of 
variance (ANOVA) revealed that there was no statistical difference (p > 0.05) in 
expression of these genes over the course of 10 passages in hNPCs cultured on 
LN- or VDP-coated surfaces. (E) SOX1, SOX2, and NESTIN immunofluorescence 
of H9-hNPCs cultured on LN and VDP for 10 passages (scale bar = 200 lm). (F) 
Flow cytometry analysis for SOX1, SOX2, and NESTIN expression in H9 hNPCs 
cultured on LN and VDP for 10 passages. (Varun et al., 2017) 
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We assessed if VDP supported the neuronal differentiation of hNPCs. HNPCs were 
cultured on laminin and on VDP coated tissue culture plates, expanded till 80% 
confluent and were differentiated by switching the culture media to neural 
differentiation media. QPCR analysis showed higher levels of expression of 
neuronal markers such as β-Tubulin-III and MAP2 in neurons cultured on Ln and 
on VDP when compared to hNPCs cultured on these substrates (figure 1-6 A and 
B). Immunofluorescence revealed the presence of cells positive for neuronal 
markers such as MAP2, β-Tubulin-III, GABA and neurofilament (NF-L) on both 
laminin and VDP cultures (Figure 1-6 C, D and E). There was no statistically 
significant difference in the number of MAP2, β-Tubulin-III and NF-L positive cells 
cultured on laminin and VDP surfaces (Figure 1-6 F). Thus, VDP also showed the 
ability to support the differentiation of hNPCs into neurons. 
In conclusion, VDP was identified as a robust, completely defined, scalable 
substrate for the expansion and differentiation of hPSC derived hNPCs on 2-D 
tissue culture surfaces. 
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Figure 1-6: Neuronal differentiation of hNPCs of VDP-coated surfaces. 
Quantitative PCR analysis for expression of neuronal markers (A) B3T and (B) 
MAP2 of neurons differentiated from H9-hNPCs on VDP and LN substrates (mean 
± S.E.M). Expression of these genes was statistically significantly higher in the 
neuronal cultures compared to hNPCs for cells cultured on both substrates 
(Student’s t-test, ***p < 0.001). There was no statistically significant (Student’s 
t-test, p > 0.05) difference between expression of these genes in neuronal 
cultures generated on LN- and VDP-coated surfaces. Immunofluorescence for (C) 
B3T and GABA (D) NF-L, and (E) MAP2 on neurons differentiated from NDC-
hNPCs on LN and VDP substrates (scale bar = 100 lM). (F) Cell counts of the 
number of B3T, MAP2, and NF-L positive cells in neuronal cultures generated 
from NDC-hNPCs on LN and VDP substrates (mean ± S.E.M). There was no 
statistically significant (Student’s t-test, p > 0.05) difference in the number of 
B3T, MAP2, and NF-L positive neurons generated on LN- and VDP-coated 
substrates. (Varun et al., 2017) 
1.4 Scale up Culture of hNPCs 
As mentioned earlier, cell based therapies require a large number of cells, 
typically of the order of 109 cells per patient per dose. Two dimensional culture 
methods have limited scalability and would therefore, not be a feasible means of 
culturing cells in such huge numbers. To overcome these limitations, adherent 
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stem cells such as hNPCs could be cultured in microcarrier based bioreactor 
systems. 
1.4.1 Microcarriers 
Microcarriers are typically spherical, bead-like structures, about 125-200 μm in 
diameter, used in scale up cultures due to their high surface area to volume ratio 
(GE Healthcare, 2005). Microcarriers were initially used to produce viral vaccines 
(Van Wezel, 1967) and are now being used to culture various cell types such as 
human Mesenchymal Stem Cells (Frauenschuh, 2007; Eibes et al., 2010), human 
Pluripotent Stem Cells (Oh et al., 2009; Fernandes et al., 2009; Phillips et al., 
2008), and Pluripotent Stem Cell derived Cardiomyocytes (Lecina, Ting, Choo, 
Reuveny & Oh, 2010). 
Micarocarriers can be non-porous, microporous or macroporous. Non-porous 
microcarriers allow cells to adhere on the surface of the beads and expose them 
to media, while microporous microcarriers have pores such that cells cannot enter 
the pores, but they create a microenvironment inside the beads and macroprous 
beads have larger pores (10-50 um in diameter) with cells growing inside the 
pores of the microcarriers. Although microporous and macroporous beads allow 
cell growth in high densities and macroporous beads protect the cells from shear 
stress, it is often difficult to harvest cells from such beads (Schaffer, Bronzino & 
Peterson, 2012). 
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Figure 1-7: Scale up culture using microcarriers. HNPCs cultured on 
spherical microcarriers. The cells forming a monolayer over a cluster of spherical 
microcarriers can be seen above. These microcarriers have a high surface area to 
volume ratio that allows cells to be cultured at higher densities than on 2D tissue 
culture plates. Scale bar= 200 um. 
Microcarriers can be surface modified to enhance attachment, for instance, 
Cytodex 1 microcarriers have dextran matrix and are positively charged (GE 
Healthcare, 2005) Cytodex 3 microcarriers consist of a thin collagen coating and 
are often coated with animal derived ECMP substrates such as Matrigel™ to 
facilitate expansion of stem cells (Nie, Bergendahl, Hei, Jones & Palecek, 2009). 
In this study, we used non porous, tissue culture treated polystyrene 
microcarriers (MC) that could be coated with the substrate of interest (Ln or VDP) 
to study the scalability of hNPC culture using these MC. 
1.4.2 Bioreactors 
Bioreactors are systems that aim at scaling up the culture of adherent and non-
adherent cells. Different types of bioreactors have been used to expand stem 
cells, for instance, stirred suspension bioreactors have been used for the 
expansion of Embryonic Stem cells (Krawetz et al., 2009; Lock & Tzanakakis, 
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2009; Oh et al., 2009; Kehoe, Jing, Lock & Tzanakakis, 2009), spinner flasks and 
perfusion bioreactors for the expansion of Mesenchymal Stem Cells (Eibes et al., 
2010; Zhao & Ma., 2005) and rotating wall vessel and hollow fibre bioreactors for 
the expansion of Haematopoietic Stem Cells (Liu, Liu, Fan, Ma & Cui, 2006; 
Sardonini & Wu, 1993). 
 
Figure 1-8: Bioreactor Configurations. (A) Spinner flask (B) Rotating wall 
vessel bioreactor (C) Wave bioreactor (D) Hollow fibre bioreactor (Schaffer, 
Bronzino & Peterson, 2012) 
Bioreactors facilitate uniform distribution of nutrients, metabolites and oxygen by 
introducing agitation in the form of stirring or by perfusion. Spinner flasks (Figure 
1-8 A) contain impellers that sparge gas bubbles throughout the medium to 
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ensure adequate supply of oxygen throughout the vessel. However, presence of 
such bubbles often creates a high shear stress environment for the cells around 
the bubbles and therefore, affects cell viability and growth. Additionally, the 
scalability of such systems is limited. 
Rotating Wall Vessel bioreactors (RWV) (Figure 1-8 B) have a gas permeable 
silicone membrane through which oxygen exchange takes place, thereby 
eliminating the need for mechanical agitation to ensure oxygen distribution. 
These vessels can either be Slow Turning Lateral Vessels with a core oxygenator 
membrane and a horizontal axis of rotation or they can be High Aspect Ratio 
Vessels with a broad oxygenator membrane on the back of the vessel. Both 
configurations of RWV bioreactors simulate a microgravity environment for cells 
to grow in- the cells/ aggregates experience almost no shear force as their 
motion is limited to a circular path about the vessel’s axis of rotation and their 
movement through the fluid medium is limited. RWVs, developed by NASA to 
simulate microgravity in space, are now being used to expand a variety of cells- 
including mesenchymal stem cells (Chen, Xu, Wan, McCaigue & Li 2006), 
haematopoietic stem cells (Kedong et al., 2010), rat neural stem cells (Lin, 
O'Shaughnessy, Kelly & Ma, 2004) etc. In addition to being a scalable system, 
the vessels allow cells to be cultured in conditions similar to those in vivo. 
Other bioreactor configurations such as hollow fibre bioreactors (Figure 1-8 D) 
and wave bioreactors (Figure 1-8 C) are also used for stem cell culture, although 
not as widely as spinner flasks and RWVs. Hollow fibre bioreactor contain a 
bundle of hollow fibres through which cells pass through and such constant 
motion of cells through the fibres and of the media around the fibres ensures 
adequate mass transport. Wave bioreactors ensure mass transport by rocking the 
cells and media, placed in a disposable pouch, back and forth. However, the 
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presence of air pocket above the medium, subjects the cells to shear stress. 
Additionally, it is difficult to monitor and control the cell growth process in these 
bioreactors. Therefore, to culture hNPCs in a physiologically relevant shear stress 
environment and to facilitate their large scale expansion, we chose to use 
rotating wall vessel bioreactors. 
In this study, we first assessed the ability of Ln and VDP MC to support the 
expansion and differentiation of hESC and hIPSC derived hNPC lines on a small 
scale and then scaled up the culture in a rotating wall vessel (RWV) bioreactor 
system to facilitate the large scale expansion of hNPCs. 
1.5 Modelling Alzheimer’s Disease 
1.5.1 Alzheimer’s Disease 
Alzheimer’s Disease (AD) is the most common form of dementia and is the sixth 
leading cause of death in the United States (Alzheimer's disease facts and figures, 
2016). It is a neurodegenerative disease marked by cognitive decline and 
memory dysfuntion. Pathologically, it is characterized by senile plaques, 
composed of Amyloid- Beta (Aβ) deposits in the extracellular space and 
neurofibrillary tangles, caused by hyperphosphorylation of tau in neurons (Perl, 
2010). 
AD can be either familial (fAD) or sporadic (sAD); the rarer familial form is 
caused by mutations in the Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1) 
or Presenilin-2 (PSEN2) genes while the more common sporadic form has been 
linked to various risk factors, particularly to polymorphisms in the APOE gene 
(Ittner & Götz, 2011). Here, we use human Neural Progenitor Cells (hNPCs) 
derived from iPSCs from patients with fAD, caused by the duplication of APP gene 
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to study AD relevant phenotypes and hNPCs derived from iPSCs from Non 
Demented Control individuals as control. 
1.5.2 Alzheimer’s Disease Pathology 
 
Figure 1-9: APP Proteolysis Amyloid Precursor Protein is cleaved through the 
non-amyloidogenic pathway by α secretase in the Aβ domain (shown in pink), 
thereby preventing the formation of Aβ peptide. However, in the amyloidogenic 
pathway, APP is cleaved by β secretase to produce a fragment with the Aβ 
domain intact. This fragment is further cleaved by γ secretase 38-42 amino acid 
residues from the extracellular N terminal (after β secretase cleavage) to 
generate Aβ peptides of varying lengths. Aβ1-42 tends to aggregate and form 
senile plaques in the brain. 
The accumulation of amyloid beta (Aβ) causing senile plaques to form, is 
attributed to the improper cleavage of its precursor protein APP. APP is a 
transmembrane protein that is processed by three enzymes- α, β and γ 
secretases. In the non-amyloidogenic pathway, APP is cleaved by α-secretase, 
secreting soluble APPα (sAPPα) into the extracellular space, leaving behind an 83 
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amino acid fragment in the membrane. This cleavage occurs in the Aβ peptide 
domain, thereby preventing the production of Aβ. However, in the amyloidogenic 
pathway, APP is cleaved by β secretase (BACE) 99 amino acids from the 
intracellular carboxy terminal of APP. This leaves behind a 99 amino acid 
fragment with the Aβ domain intact, in the membrane which is then cleaved by γ 
secretase 38-43 amino acids from the first amino acid residue in the fragment left 
from the β secretase cleavage. This causes the release of Aβ peptide of varying 
lengths into the extracellular space, with Aβ1-40 being the most abundant to Aβ1-
42, aggregating to form plaques. Additionally, the presence of intracellular Aβ and 
oligomeric Aβ species has been shown to have toxic effects on neurons (LaFerla, 
Green & Oddo, 2007). 
Tau is a microtubule associated protein that is primarily found in axons and is 
involved in axonal transport regulation and microtubule stabilization. Tau can 
undergo phosphorylation at 84 sites, at serines, threonines and tyrosines and this 
phosphorylation destabilizes the microtubule. Particularly, phosphorylation at 
Threonine 231, Serine 396 and Serine 422 causes tau to aggregate to form 
filaments (Gong & Iqbal, 2008). Thus, hyperphosphorylation of tau as observed in 
AD, destabilizes microtubules and leads to the formation of neurofibrillary tangles 
(Ittner & Götz, 2011). 
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Figure 1-10. Formation of neurofibrillary tangles Tau is a microtubule 
associated protein that binds to microtubules and stabilizes them. 
Hyperphosphorylation of tau, inhibits its binding to microtubules, thereby 
destabilizing them. Additionally, hyperphosphorylation of tau causes it to be 
sequestered, leading to the formation of neurofibrillary tangles. (Brunden, 
Trojanowski & Lee, 2009). 
The prevailing amyloid cascade hypothesis posits the deposition of amyloid beta 
as the central event that leads to neurodegeneration in AD. According to this 
hypothesis, the formation of Aβ peptide, and its subsequent oligomerization leads 
to abnormal phosphorylation of tau, thereby causing neurofibrillary tangles to 
form, which in turn leads to neuronal death and synaptic dysfunction (Hardy & 
Selkoe, 2002). In this study, we have assessed the levels of secreted Aβ1-40 and 
Aβ1-42 and phosphorylated tau relative to total tau in fAD patient derived hNPCs 
(APP-hNPC) and in Non Demented Control hNPCs (NDC-hNPC).  
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2. Materials and Methods 
2.1 hNPC Culture 
NDC-, HES3- and APP-hNPC were cultured on PLO/Ln coated tissue culture 
treated plates. The plates were first coated with poly-L-ornithine (PLO) (4 ug/mL) 
solution and incubated at 37˚C overnight and washed twice with 1x DPBS. The 
plates were then coated with mouse laminin (Ln) (4 ug/mL) and incubated at 
37˚C overnight and were washed twice with 1x DPBS before use. HNPCs were 
plated on PLO/Ln plates at 1-2 x 104 cells/cm2 and were routinely passaged upon 
reaching 80% confluency. Neural Expansion Media (1x DMEM-F12, 0.5% (v/v) N2 
supplement, 0.5% (v/v) B27 supplement) with 30 ng/mL EGF and 30 ng/mL 
FGF2 was used to culture the cells. 
2.2 Microcarrier Culture 
Tissue cultured treated polystyrene microcarriers (Corning Enhanced Attachment 
microcarriers) were coated with the substrate of interest (PLO/Ln or Vitronectin 
Derived Peptide) as follows: 
Sterile microcarriers were weighed and suspended in 1x DPBS. The required 
amount of microcarriers were transferred to Eppendorf tubes/ conicals and were 
suspended in 4 ug/mL PLO solution and incubated at 37˚C overnight after which 
the PLO was removed using micropipettes and the PLO- coated microcarriers 
were washed twice with 1x DPBS. These microcarriers were then suspended in 4 
ug/mL mouse laminin solution and incubated at 37˚C overnight. 
For coating the microcarriers with the peptide (VDP), the required amount of 
microcarriers were suspended in 0.5mM solution of the peptide and incubated at 
37˚C for 48 hours. 
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The microcarriers were washed once with 1x DPBS and once with NEM before 
use.  
HNPCs cultured on PLO/Ln plates were seeded on PLO/Ln or VDP coated 
microcarriers in NEM containing 5uM Rho kinase inhibitor (Y-27632) to aid single 
cell survival and were transferred to 6 well Ultra Low Attachment plates. For the 
long term expansion and differentiation experiments, hNPCs were seeded at 1.5 
million cells/well with 1 mg/mL of PLO/Ln or VDP microcarriers. The plates were 
placed in a 37˚C/5% CO2/95% humidity tissue culture incubator with half the 
final culture volume in each well to allow for maximum cell attachment on the 
microcarriers for 12 hours after which the rest of the culture media containing 
Rho kinase inhibitor was added and the plates were then placed on an orbital 
shaker with the agitation set at 95 rpm. Three fourth of the media was changed 
after 24 hours and half the media was changed every 24 hours after that. 
Upon confluency, the cell-microcarrier aggregates were transferred to conicals, 
centrifuged at 200g for 3-5 minutes for the aggregates to settle and the media 
was aspirated. The aggregates were then resuspended in Accutase and were 
transferred back to Ultra Low Adhesion plates and were incubated at 37˚C for 10 
minutes (5 minutes with no agitation and 5 minutes on the orbital shaker). Media 
was added to each well to inactivate the Accutase and the aggregates were gently 
pipetted up and down to detach the cells from the microcarriers. This cell- 
microcarrier suspension was then passed through a 40 um cell strainer to obtain 
a single cell suspension free of the microcarriers. The cells were the centrifuged 
at 200g for 5 minutes, resuspended in media with rho kinase inhibitor, counted 
using a haemocytometer and were seeded on washed, freshly coated 
microcarriers. 
  For differentiation, hNPCs were expanded on microcarriers for 4-5 days till 
confluent and three fourth of the media was changed to Neural Differentiation 
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Media (1x DMEM-F12, 0.5% (v/v) N2 supplement, 0.5% (v/v) B27 supplement) 
with 20 ng/mL BDNF and 20 ng/mL GDNF. The cells were cultured in this 
differentiation media for 18 days after which Neural Base Media (1x DMEM-F12, 
0.5% (v/v) N2 supplement, 0.5% (v/v) B27 supplement) was used for the rest of 
the culture duration. This protocol was followed unless otherwise specified. 
For the density gradient/maximization experiments, the number of cells seeded 
and the microcarrier concentration were varied as mentioned in table 1. Three 
fourth media was changed every 24 hours. 
2.3 Bioreactor Culture 
Synthecon 55mL STLV was prepared according to manufacturer’s instructions. 
Briefly, the vessel was dismantled and immersed in a mild detergent for an hour 
after which it was cleaned in Milli- Q water. The vessel was soaked in Milli-Q 
water overnight and was air dried before autoclaving at 121˚C for 20 minutes. 
The vessel was washed in Milli-Q water and was autoclaved before beginning 
each experiment. 
HNPCs cultured on microcarriers in 6 well Ultra Low Adhesion plates were seeded 
on PLO/Ln or VDP microcarriers (coated as mentioned above) and were 
transferred to the bioreactor vessel using its fill port. The vessel was filled with 
media and bubbles were removed using syringes. The vessel was rotated at 10 
rpm to begin with and with the formation of clusters and increase in their size, 
the rpm was increased.  
Samples were taken through the fill port every day for imaging, obtaining cell 
counts and monitoring cell viability. 30 mL media was removed everyday and the 
cell-microcarrier aggregates were mixed throughout the rest of the culture 
volume (25 mL). Two ~0.5 mL samples were taken through the fill port and 
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transferred to 6 well Ultra Low Adhesion plates for imaging. These cells were 
stained with Propidium Iodide to monitor cell viability. 
When confluent, the microcarrier aggregates were transferred to 50 mL conicals 
and were centrifuged and the media was aspirated. Accutase was added to the 
conicals and the aggregates were transferred to a 6 well Ultra Low Adhesion plate 
with the aggregates evenly divided among all 6 wells. The plate was incubated at 
37˚C for 10 minutes with no agitation after which media was added to inactivate 
the Accutase. The cells were separated from the microcarriers by passing them 
through 40 um cell strainers. The cells were then centrifuged at 200g for 5 
minutes and resuspended in appropriate volume of media for obtaining cell 
counts and for running other assays.  
2.4 Quantitative PCR 
RNA was isolated from cells using Nucleospin RNA kit (Macherey Nagel). cDNA 
was synthesised from 1ug of the isolated RNA using iScript Reverse Transcription 
Supermix (Bio-Rad). QPCR was performed using iTaqTM Universal SYBR® Green 
Supermix (Bio Rad) and the primers listed in Table 1 on a CFX384 TouchTM Real-
Time PCR Detection System. The reaction involved a 2 minute elevation to 95˚C, 
followed by 40 cycles at 95˚C for 5 seconds and 60˚C for 30 seconds. 18s rRNA 
levels were used as endogenous control and the gene expression was quantified 
using the ΔΔ Ct method. 
2.5 Flow Cytometry 
Cells cultured on microcarriers were dissociated using Accutase, triturated, 
passed through a 40 um cell strainer and washed once with stain buffer (BD 
Biosciences). The cells were fixed using fixation buffer (BD Cytofix fixation buffer) 
at room temperature for 30 minutes. The cells were washed twice with stain 
buffer and permeabilized using BD Phosflow Perm Buffer III at 4˚C for 30 
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minutes. The cells were washed twice and stained using conjugated antibodies for 
SOX1, SOX2 and NESTIN as listed in Table 2 at 4˚C overnight. The cells were 
washed twice and resuspended in stain buffer and analysed on Accuri C6 flow 
cytometer (BD Biosciences). 
For the propidium iodide staining, the cell suspension was washed once with 1x 
DPBS and resuspended in stain buffer. The cells were stained with 2mg/mL 
propidium iodide for 1-2 minutes in dark and were analysed on Accuri C6 flow 
cytometer (BD Biosciences).  
2.6 Enzyme Linked Immunosorbent Assay (ELISA) 
Cells were cultured in media prepared using phenol-red free DMEM/F12 for 48 
hours prior to media collection. The 24 hour conditioned media was collected and 
concentrated 10x by centrifuging at 14,000 g for 30 minutes and reverse spinning 
for 1.5 minutes at 4˚C. The samples were stored in -80˚C until use. 
Commercially available ELISA kits for Aβ40 and Aβ42 (Life Technologies catalog 
numbers KHB3481 and KHB3441 respectively) were used to measure the level of 
Aβ40, Aβ42 secreted by hNPCs, according to the manufacturer’s protocol. The 
samples were incubated on wells pre-coated with monoclonal antibody specific for 
the –NH2 terminal of Aβ, along with detection (primary) antibody specific for the 
–COOH terminal of Aβ and the plate was incubated for 3 hours at room 
temperature with shaking (250 rpm). The wells were washed four times and were 
incubated with HRP conjugated secondary antibody for 30 minutes at room 
temperature. The plate was washed four times with the wash buffer and the was 
incubated with the stabilized chromogen (TMB) for 30 minutes at room 
temperature in dark and the reaction was stopped using sulfuric acid, after which 
the absorbance at 450 nm was read. 
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For the phorphorylated tau and total tau ELISAs, the cell pellet was collected after 
dissociation with Accutase, trituration and passing through cell strainers. The cells 
were lysed in 0.1% TBST with protease inhibitors with vortexing and the lysate 
was centrifuged at 16000 g for 30 minutes at 4˚C to collect the supernatant, 
which was stored in -80˚C until use. A Bradford assay was done to determine 
total protein (absorbance read at 595 nm) and 100 uL of the lysates diluted to 
50ug/mL were used for the phosphorylated & total tau ELISAs. Commercially 
available kits for phosphorylated tau (Life Technologies, catalog number 
KHB8051) and total tau (Life Technologies, catalog number KHB0041) were used 
for this study- briefly, the samples were incubated in wells pre-coated with 
monoclonal antibody specific to tau protein phosphorylated at threonine 231 for 
phosphorylated tau assay and antibody specific to human tau protein for the total 
tau assay for 2 hours. The wells were washed four times and were incubated with 
the detection antibody for an hour at room temperature. The wells were washed 
four times and the HRP labelled secondary antibody was added to wells. After an 
incubation period of 30 minutes at room temperature, the wells were washed four 
times and the stabilized chromogen (TMB) was added. The plate was incubated in 
dark for 30 minutes at room temperature after which the stop solution was 
added. The absorbance was read at 450 nm. Absorbance readings for all ELISAs 
were done using Synergy multi mode plate reader. 
2.7 Immunofluorescence 
2.7.1 Confocal Imaging 
Cells cultured on microcarriers were fixed using BD Cytofix fixation buffer for 30 
minutes at room temperature, after which the cell-microcarrier aggregates were 
was washed twice with 1x DPBS. The aggregates were permeabilized in BD 
Phosflow Perm Buffer III for 30 minutes at 4˚C and then washed twice with 1x 
DPBS. The aggregates were stained using the primary antibodies listed in table 2 
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and incubated at 4˚C overnight. Excess/unbound antibodies were washed off by 
rinsing with 1x DPBS twice and the aggregates were stained with the appropriate 
secondary antibodies (as listed in table 2) and incubated at room temperature for 
1 hour. The cell-microcarrier aggregates were washed twice with 1x DPBS and 
were stained with Hoescht 33342 (1:5000) for 10 minutes at room temperature, 
followed by two washes with 1x DPBS and resuspension in enough 1x DPBS to 
transfer them to 6 well Ultra Low Adhesion plates where the samples were stored 
(at 4˚C) until imaging using either EVOS fluorescence microscope or Leica TCS 
SP5 AOBS Spectral Confocal System. The aggregates were transferred to double 
cavity slides and were mounted in Vectashield mounting medium for imaging 
using the confocal microscope. Laser power settings are as mentioned in table 3 
and the PMT gain for each image stack was set to ensure no saturation 
throughout the stack. 
2.7.2 Plating Microcarriers 
Neurons cultured on microcarriers were incubated in Accutase for 5 minutes at 
37˚C and were gently mechanically dissociated to break apart the clusters into 
smaller aggregates. Media was added to inactivate the Accutase and the 
aggregates were resuspended in the appropriate media with Rho kinase inhibitor 
(Y-27632). The aggregates were plated on Matrigel™ coated 12 well plates and 
the media was changed on day 1, followed by half media changes until fixation. 
Once the plated aggregates had spread out, the cells were fixed using BD Cytofix 
Fixation Buffer for 15 minutes at room temperature. The cells were washed twice 
with stain buffer and the permeabilized using BD Phosflow Perm Buffer III for 30 
minutes at room temperature. The cells were washed twice with stain buffer and 
then stained with primary antibodies as listed in table 2, overnight at 4˚C. The 
cells were washed twice and stained with the appropriate secondary antibody for 
one hour at room temperature and then with Hoescht 33342 for 10 minutes at 
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room temperature. The cells were washed twice after staining with the secondary 
antibodies as well as after staining with Hoescht. Samples were imaged using 
EVOS fluorescence microscope. 
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3. Results 
3.1 Long term expansion of hNPCs on VDP microcarriers 
We previously identified VDP as a substrate capable of supporting long term 
expansion and differentiation of several ESC and iPSC line derived hNPCs on 
tissue culture treated polystyrene plates. Next, we sought to identify if the 
peptide would support the culture of these hNPCs on tissue cultured treated 
polystyrene microcarriers. HNPCs derived from Non-Demented Control hiPSCs 
(NDC-hNPCs) were cultured on VDP coated microcarriers (VDP MC) and on 
laminin coated microcarriers as control (Ln MC) for more than 20 passages. The 
cells adhered to both VDP and laminin microcarriers, forming aggregates and 
expanding up to four fold by day 4 or 5 of culture (Figure 3-1 A and Figure 3-2 
A). The doubling time of hNPCs on VDP MC was similar to that of hNPCs cultured 
on VDP coated 2D tissue culture plates. However, VDP MC supported 1.5±0.1 
million cells/mL of culture volume when confluent as opposed to 2D VDP coated 
plates which supported only 0.9±0.04 million cells/mL. Also, the initial cell 
seeding density and microcarrier concentrations could be optimized to result in 
4.5 million cells/mL of culture volume with VDP MC culture. The hNPCs cultured 
on VDP and Ln MC expressed multipotency markers such as SOX1 and SOX2 
throughout 10 passages as shown by qPCR analysis, with no significant difference 
in the expression of these genes across passages (Figure 3-1.B and Figure 3-
2.B). Additionally, flow cytometry analysis of hNPCs cultured on VDP and Ln MC 
for 20 passages revealed that >99% of the cells express these hNPC markers 
(Figure 3-1. E and Figure 3-2.E) and immunofluorescence on passage 13 hNPCs 
on VDP showed the expression of SOX2 and NESTIN (Figure 3-1. D).  
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Figure 3-1: Long-term culture and expansion of NDC-hNPCs on VDP-
coated microcarriers (MCs). (A) Representative phase contrast images of 
NDC-hNPCs cultured on VDP-coated MCs for 20 passages (scale bar = 250 μm). 
(B) Doubling time of NDC-hNPCs cultured on VDP-coated 2-D and MC surfaces. 
Data is presented as the mean ± S.D of the doubling time over the course of 20 
passages. There was no statistical difference in the doubling time of hNPCs grown 
on MC and 2-D surfaces (Student’s t-test, p = 0.626). (C) Quantitative PCR 
(qPCR) analysis for expression of hNPC multipotency markers SOX1 and SOX2 for 
in NDC-hNPCs cultured VDP-coated MCs for 1, 5, and 10 passages (mean ± 
S.E.M). One-way analysis of variance (ANOVA) revealed that there was no 
statistical difference (SOX1, p = 0.099; SOX2, p = 0.118) in expression of these 
genes over the course of 10 passages in hNPCs cultured on VDP-coated 
microcarriers. (D) SOX2 and NESTIN immunofluorescence of NDC-hNPCs cultured 
on VDP-coated MCs for 13 passages. Cross-section of the MC carrier cultures is 
shown in the upper panels (scale bar = 50 μm) and z-stack projection is shown in 
the lower panels (scale bar = 100 μm). (E) Flow cytometry analysis for SOX1, 
SOX2, and NESTIN expression in NDC-hNPCs cultured on VDP-coated 
microcarriers for 20 passages. 
 
We also tested the ability of VDP MC to support the long term expansion of ESC 
derived hNPCs by culturing HES-3 hNPC on VDP MC for more than 10 passages. 
HES-3 hNPCs were also cultured on Ln MC as control and on VDP and Ln coated 
2-D tissue culture plates to assess the scalability achieved using MC. The cells 
adhered to both Ln MC and VDP MC (Figure 3-3 A) and showed doubling times 
similar to Ln and VDP coated 2-D surfaces (Figure 3-3 B). VDP MC showed the 
29 
 
ability to support 0.83±0.04 million cells/mL of culture volume when confluent. 
These cells expressed hNPC markers SOX1, SOX2 and NESTIN throughout 10 
passages when cultured on Ln MC and on VDP MC as shown by flow cytometry 
analyses (Figure 3-3.D). Additionally, immunofluorescence on passage 13 hNPCs 
on VDP MC revealed the expression of the NPC marker NESTIN (Figure 3-3 C).  
Thus, VDP MC can support the long term expansion of both iPSC and ESC derived 
hNPCs on levels similar to Ln MC. Also, MC can be used to scale up of the culture 
of these hNPCs when compared to conventional 2-D tissue culture surfaces. 
 
 
Figure 3-2: Long-term culture and expansion of NDC-hNPCs on LN-coated 
microcarriers (MCs). (A) Representative phase contrast images of NDC-hNPCs 
cultured on LN-coated MCs for 20 passages (scale bar = 250 μm). (B) Doubling 
time of NDC-hNPCs cultured on LN-coated 2-D and MC surfaces. Data is 
presented as the mean ± S.D of the doubling time. There was no statistical 
difference in the doubling time of hNPCs grown on MC and 2-D surfaces 
(Student’s t-test, p = 0.358). (C) Quantitative PCR (qPCR) analysis for expression 
of hNPC multipotency markers SOX1 and SOX2 for in NDC-hNPCs cultured LN-
coated MCs for 1, 5, and 10 passages (mean ± S.E.M). One-way analysis of 
variance (ANOVA) revealed that there was no statistical difference (SOX1, p = 
0.565; SOX2, p = 0.570) in expression of these genes over the course of 10 
passages in hNPCs cultured on LN-coated microcarriers. (D) NESTIN 
immunofluorescence of NDC-hNPCs cultured on LN-coated MCs for 13 passages. 
Cross-section of the MC carrier cultures is shown on the left panel (scale bar = 50 
μm) and z-stack projection is shown on the right panels (scale bar = 100 μm). 
(E) Flow cytometry analysis for SOX1, SOX2, and NESTIN expression in NDC-
hNPCs cultured on LN-coated microcarriers for 20 passages. 
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Figure 3-3: Long-term culture and expansion of HES3-hNPCs on VDP- and 
LN-coated microcarriers (MCs).  (A) Representative phase contrast images of 
HES3-hNPCs cultured on VDP- (left panel) and LN-coated (right panel) for 10 
passages. (B) Doubling time of HES3-hNPCs cultured on 2-D and MC surfaces 
coated with VDP (left panel) and LN (right panel). Data is presented as the mean 
± S.D of the doubling time. There was no statistical difference in the doubling 
time of hNPCs grown on MC and 2-D surfaces coated with VDP (Student’s t-test, 
p = 0.941) and LN (Student’s t-test = 0.542). (C) NESTIN immunofluorescence of 
HES3-hNPCs cultured on VDP-coated MCs for 13 passages (scale bar = 50 μm). 
(D) Flow cytometry analysis for SOX1, SOX2, and NESTIN expression in HES3-
hNPCs cultured on VDP- (top panels) and LN-coated microcarriers for 11 
passages. 
 
3.2 Differentiation of iPSC derived hNPC 
HNPCs have the ability to differentiate into neurons, glial cells and 
oligodendrocytes. To assess if the hNPCs cultured on VDP MC retain their ability 
to differentiate, we expanded NDC-hNPCs on VDP MC for 4-5 days till confluent 
and started differentiating these cells by switching the media to neural 
differentiation media and continued to culture the cells in NDM for 30 days. QPCR 
analysis comparing the expression of various hNPC, neuronal, neurotransmitter, 
glial and cortical markers in passage 1 hNPCs and day 30 neurons cultured on 
31 
 
VDP MC reveal the upregulation of neuronal markers such as TUBB3, a 
microtubule protein and RBFOX3, a marker for neuronal nuclei and glial markers 
in day 30 neurons (Figure 3-4 A). On the other hand, hNPC markers such as 
Nestin, SOX1 and SOX2 were downregulated in day 30 neurons when compared 
to passage 1 hNPCs on VDP MC (Figure 3-4 A). RNA Seq analysis of day 30 
neurons and passage 10 hNPCs on VDP MC also revealed a similar pattern of 
downregulation of genes associated with NPC phenotype (such as NES, SOX1, 
SOX2 and PAX6) and upregulation of genes associated with neuronal phenotype 
(such as DCX, TUBB3, MAP2) (Figure 3-4 B). Similarly, day 30 neurons cultured 
on Ln MC expressed higher levels of neuronal, neurotransmitter, cortical and 
astrocyte markers than neurons cultured on Ln coated 2-D plates (Figure 3-6 A). 
Immunofluorescence on day 31 neurons on VDP MC also show the expression of 
TUBB3 (Figure 3-4 D). Additionally, flow cytometry analysis of day 65 neurons on 
VDP MC and Ln MC indicate the presence of NEUN (neuronal nuclei) positive cells 
(Figure 3-4 C and Figure 3-6 B). Thus, VDP and Ln MC were shown to support 
neuronal differentiation in suspension cultures. 
Next, we dissociated neurons cultured on VDP MC for 69 days in suspension, 
plated the dissociated aggregates on Matrigel™ and allowed the cells to spread 
out for 7 days for their morphologies to be apparent. These plated cells were 
positive for neuronal markers MAP2, TUBB3 and GABA and for glial marker GFAP 
(Figure 3-4 E). This indicates that neurons cultured on MC in suspension could be 
harvested for practical applications by dissociating and plating without the loss of 
their neuronal morphology or characteristics.  
We compared the maturity of neurons generated on MC surfaces and those 
generated using conventional 2-D culture. RNA Seq analysis comparing the gene 
expression profiles of day 8 NDC neurons cultured on VDP coated 2D plates and 
day 30 NDC neurons cultured on VDP MC showed the upregulation of several 
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neuronal and neurotransmitter markers such as SYN1, DLG and NEFM in day 30 
neurons on VDP MC (Figure 3-5 A). Gene ontology analysis revealed the 
upregulation of genes involved in the regulation of neurogenesis, neuron 
projection and synapse formation in day 30 neurons on VDP MC (Figure 3-5 E and 
F). Genes related to post mitotic neuron and synapse formation, Ca2+, K+, Na+ 
and Cl- ion channels and secretion and release of neurotransmitters such as GABA 
(gamma aminobutyric acid), glutamate and acetylcholine were significantly 
upregulated in day 30 neurons cultured on VDP MC compared to day 8 neurons 
on VDP coated 2-D plates and hNPCs cultured on VDP coated 2-D and MC 
surfaces (Figure 3-5 B, C and D). Taken together, these results indicate that 
neurons cultured on MC surfaces are more mature than those obtained by 
differentiating hNPCs on 2-D surfaces. 
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Figure 3-4: Differentiation of NDC-hNPCs on VDP-coated microcarriers 
(MCs). (A) Quantitative PCR (qPCR) analysis for expression of hNPC 
multipotency-, neuronal-, neurotransmitter-, cortical-, and astroglial-related 
markers in day 30 (D30) differentiated cultures. (B) RNA sequencing (RNA-seq) 
analysis comparing gene expression profiles of hNPC and D30 differentiated 
cultures. Genes with RPKM values greater than 1 were plotted. Genes showing 
altered expression with FDR < 0.05 and more than 2 fold changes were 
considered significantly upregulated (red) or downregulated (green). (C) Flow 
cytometry analysis for NEUN expression in D65 differentiated cultures. (D) TUBB3 
immunofluorescence of D31 cultures. Cross-section of the MC carrier cultures is 
shown in the upper panels (scale bar = 100 μm) and z-stack projection is shown 
in the lower panels (scale bar = 50 μm). Immunofluorescence for (E) MAP2, 
GFAP, (F) GABA, and TUBB3 in differentiated MC cultures dissociated on D69, 
plated, and cultured for 7 days after dissociation (scale bar = 200 μm). 
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Figure 3-5: Comparison of differentiation of NDC-hNPCs on VDP-coated 
2-D and microcarrier (MC) surfaces. (A) RNA sequencing (RNA-seq) analysis 
comparing gene expression profiles of hNPCs differentiated on 2-D and MC 
surfaces. Genes with RPKM values greater than 1 were plotted. Genes showing 
altered expression with FDR < 0.05 and more than 2 fold changes were 
considered significantly upregulated (red) or downregulated (green). Genes that 
were significantly upregulated on differentiated cultures generated on MC 
surfaces include those related to (B) post-mitotic neurons and synapse formation, 
(C) acetylcholine (ACH), γ-aminobutyric acid (GABA), and glutamate (GLU) 
neurotransmitter synthesis, release, and transmission, (D) potassium (K+), 
calcium (Ca2+), sodium (Na+), and chloride (Cl-) ion channels involved in action 
potential generation. Gene ontology (GO) analysis identified (E) cellular 
components and (F) biological processes related to neuron maturation, axon 
generation, and synapse formation were significantly enriched in differentiated 
cultures generated on MCs. 
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Figure 3-6: Differentiation of NDC-hNPCs on LN-coated microcarriers 
(MCs). (A) Quantitative PCR (qPCR) analysis for expression of hNPC 
multipotency-, neuronal-, neurotransmitter-, cortical-, and astroglial-related 
markers in day 30 (D30) differentiated cultures. (B) Flow cytometry analysis for 
NEUN expression in D65 differentiated cultures. 
 
3.3 Bioreactor scale up culture 
Since Ln and VDP MC could support the expansion of hNPCs over multiple 
passages on a small scale, in 6 well plates, we assessed if these MC could be 
used in a bioreactor system to further scale up the culture of hNPCs. NDC-hNPCs 
were expanded on Ln MC in 6 well plates for 7 days at cell and microcarrier 
densities optimized to maximize final hNPC counts. These hNPCs expanded on a 
small scale were seeded at a density of 0.36 million cells/mL with 10 mg/mL Ln 
MC in a rotating wall vessel (RWV) bioreactor (Figure 3-7 A) and expanded for 6 
36 
 
days till confluent (Figure 3-7 B). Samples were taken every day to obtain cell 
counts and assess cell viability (by propidium iodide- PI staining). More than a 
five-fold change of cell density was observed by day 4 with 2.01±0.07 million 
cells/mL (Figure 3-7 C). Thus, around 110 million cells were obtained by 4 days 
of expansion by seeding 20 million cells in the 55mL bioreactor. Flow cytometry 
analyses revealed the expression of NESTIN, SOX1 and SOX2 by a high 
percentage (>88%) of the cells cultured in the bioreactor (Figure 3-7 D).  
 
Figure 3-7: Large-scale expansion of NDC-hNPCs on Ln-coated 
microcarriers (MCs) in rotating wall vessel (RWV) bioreactor. (A) Image of 
RWV bioreactor inside tissue culture incubator. (B) Phase contrast images of 
samples taken from the bioreactor on days 1 through 6. Scale bar= 1000 um. (C) 
Live cell concentration on days 1 through 6 of bioreactor culture. Cell viability and 
cell counts were analysed on a flow cytometer by staining samples taken from the 
bioreactor with PI. The total live cell count in the bioreactor vessel was 
extrapolated based on this sample cell count, after accounting for the sample 
volumes withdrawn every day and the live cell concentration was calculated by 
dividing this extrapolated live cell count by the vessel volume (55 mL). (D) Flow 
cytometry analysis for SOX1, SOX2, and NESTIN expression in NDC-hNPCs 
cultured on Ln-coated MCs in the RWV bioreactor. 
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3.4 fAD patient derived hNPCs (APP(Dp) hNPC) cultured on microcarriers 
recapitulate AD 
To be used for drug screening purposes, we require patient derived hNPCs to be 
expanded on a large scale, with the cells faithfully recapitulating disease 
phenotypes. Since MC surfaces could support the large scale expansion of Non-
Demented Control hNPCs, we assessed if AD patient derived hNPCs expanded on 
MC could display disease relevant phenotypes, namely Aβ1-40 and Aβ1-42 secretion 
and elevated levels of phosphorylated tau. 
Somatic cells from an fAD patient with duplication of APP gene, were 
reprogrammed to form iPSCs which were further differentiated to form hNPCs, 
referred to as APP(Dp) hNPCs here. These APP(Dp) hNPCs and NDC-hNPCs (used 
as control) were expanded on Ln MC for 5 days till confluent and the conditioned 
media was collected to assess the levels of Aβ1-40 and Aβ1-42. Cell lysates were 
used to assess the levels of phosphorylated and total tau. APP(Dp) hNPCs showed 
significantly higher concentrations of Aβ1-40 (p<0.001) and Aβ1-42 (p<0.05) 
compared to NDC-hNPCs (Figure 3-8). However, the level of phosphorylated tau 
relative to total tau was not significantly elevated in APP(Dp) hNPCs cultured on 
Ln MC when compared to NDC hNPCs (data not shown). 
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Figure 3-8: Analysis of Alzheimer’s disease (AD)-related phenotypes in 
neural cells cultured on microcarrier (MC) surfaces. HNPCs derived from 
nondemented control (NDC) and AD-APP(Dp) hiPSCs were cultured on Ln MC 
surfaces for 5 days and analyzed for secreted (A) Aβ40 and (B) Aβ42 levels 
(mean ± S.E.M.). Comparisons made against NDC hNPCs ((Student’s t-test, 
*p<0.05, ***p<0.001). 
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4. Discussion 
The clinical and therapeutic use of hNPCs require the development of completely 
defined, scalable culture systems. We previously identified a synthetic peptide, 
VDP, derived from the cell binding domain of Vitronectin, an extracellular matrix 
protein (ECMP), capable of supporting the long term expansion and differentiation 
of various ESC and iPSC derived hNPC lines on 2-D tissue culture treated plates. 
In this study, we scaled up the culture of hNPCs using VDP coated microcarriers. 
VDP MC were able to support the long term expansion of ESC and iPSC derived 
hNPCs over multiple passages and supported higher fold changes in cell densities, 
compared to VDP coated 2-D surfaces. HNPCs cultured on VDP MC showed high 
levels of expression of NPC markers such as NESTIN, SOX1 and SOX2 throughout 
multiple passages. 
VDP MC also showed the ability to support the neuronal differentiation of hNPCs, 
and produced mature neurons expressing several neuronal, neurotransmitter and 
cortical markers. Generally, the neurons differentiated from hNPCs cultured on 2D 
surfaces do not adhere to the surface for more than a few weeks and are often 
fragile, limiting their potential for long term studies. However, the neurons 
cultured on MC were found to be robust in their ability to adhere to the substrate 
and could be cultured in suspension for long periods of time (>120 days). These 
neurons cultured on MC were found to be more mature than the ones cultured on 
2-D surfaces. 
HNPCs were cultured in microcarrier based bioreactor systems and were found to 
expand more than five-fold, up to 110 million cells in 4 days. These cells showed 
high levels of expression of NPC markers, indicating that hNPCs can be expanded 
on a large scale in microcarrier based bioreactor system.  
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fAD patient derived hNPCs with duplication of APP gene, when cultured on MC 
displayed AD relevant phenotypes such as high levels of secreted Aβ in the 
culture medium. The levels of both Aβ1-40, and the plaque forming Aβ1-42 were 
found to be elevated, indicating that patient derived cells can be cultured on MC 
and can be used for disease modelling and drug screening. 
5. Future Work 
Vitronectin Derived Peptide has been identified as a completely defined, scalable 
substrate for culturing hNPCs. This study shows that hNPCs can be cultured on a 
large scale in Ln microcarrier based RWV bioreactors. Future work would involve 
culturing hNPCs on VDP MC in RWV bioreactor to allow the scale up of hNPC 
culture in standard, xeno-free and chemically defined conditions. The final cell 
counts obtained from the bioreactor can also be maximised by varying the initial 
cell seeding density and the microcarrier concentration.  
Such large scale culture of hNPCs would also allow for culturing of neurons on a 
large scale. Characterization of such neurons differentiated in the bioreactor by 
examining their gene expression profiles and their electrophysiological properties 
would also be of interest. 
This study looks at the AD relevant phenotypes shown by hNPCs derived from 
fAD patients. Although rare, familial form of AD has been studied widely and the 
mutations associated with fAD have been valuable in developing animal models of 
the disease. However, the mechanisms of the sporadic form of the disease are 
still poorly understood and animal models would not be suitable for studying the 
same. By developing a chemically defined, scalable system of culturing hNPCs, 
we can now expand sAD patient derived hNPCs on a large scale to model the 
disease and to allow for drug screening. 
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APPENDIX A 
TABLE 1: FORWARD AND REVERSE PRIMERS USED FOR RT-QPCR 
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Gene Forward Reverse 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
NESTIN CGCACCTCAAGATGTCCCTC CAGCTTGGGGTCCTGAAAGC 
SOX2 TTTGTCGGAGACGGAGAAGC CCCGCTCGCCATGCTATT 
MAPT AGGGGGCTGATGGTAAAACG TTGCTTAGTCGCAGAGCTGG 
NCAM GATGCGACCATCCACCTCAA CCAGAGTCTTTTCTTCGCTGC 
ACHE CACAGGGGATCCCAATGAGC CGTCGAGCGTGTCGGTG 
GABRA TGCGGATTTCGTCCTGACTT AATCTGCAGCTCTGAATTGTGC 
SLC17A7 AGCTGGGATCCAGAGACTGT CCGAAAACTCTGTTGGCTGC 
SLC6A4 AGAATTTTACACGCGCCACG GAGGTCTTGACGCCTTTCCA 
EAAT3 TGGTGCTAGGCATTACCACA CCGGATACGTTGGAATCCAGT 
GFAP AACCTGCAGATTCGAGGGGG GGCGGCGTTCCATTTACAATC 
ASCL1 TCCCCCAACTACTCCAACGA GCGATCACCCTGCTTCCAAA 
BCL11B CTCATCACCCAGGCTGACC GGCCACTTGGCTCCTCTATC 
CUX1 TCTCAAGATGGCGGCCAATG TTGCGCAAATCCTCTGGAGT 
EMX1 GAGACGCAGGTGAAGGTGTG CACCGGTTGATGTGATGGGA 
EMX2 ATCCGTCCACCTTCTACCCC ACCATACTTTTACCTTGGAAGCG 
FOXG1 TGCCAAGTTTTACGACGGGA AGGGTTGGAAGAAGACCCCT 
LHX9 TACCACTCTAGAGGCAGCCA GGCATGCCCGCGTCG 
SATB2 CCGCACCAGAAGAAGACACC CAGGGACTGCTCACGGTCT 
TUBB3 GAGGGGCATCTCTTGAGAACAA CCCAGAACTGTGGACGCCT 
RBFOX3 TGGGACGATCGTAGAGGGAC CTTCCAGCCGTTGGTGTAGG 
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APPENDIX B 
TABLE 2: ANTIBODIES USED FOR FLOW CYTOMETRY AND 
IMMUNOFLUORESCENCE 
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Antibody Vendor Catalog 
Number 
Concentration 
Used 
Goat anti-SOX2 Santa Cruz SC-17320 1:50 
Mouse anti-SOX1 BD BD 56749 1:50 
Mouse anti-Nestin BD BD 560341 1:50 
Mouse anti-B3T Fitzgerald 10R-T136A 1:1000 
Rabbit anti-GABA Millipore AB15415 1:200 
Mouse anti-GFAP Millipore AB360 1:500 
Rabbit anti-MAP2 Millipore AB5622 1:500 
Alexa-647 Mouse 
anti-SOX2 
BD BD 560294 1:10 
Alexa-647 Mouse 
anti-Nestin 
BD BD 560341 1:10 
PerCp-Cy5.5 Mouse 
anti-SOX1 
BD BD 561549 1:10 
Alexa 647 Donkey 
anti-Mouse 
Life Technologies A-31571 1:200 
Alexa 647 Donkey 
anti-Goat 
Life Technologies A-21447 1:200 
Alexa 488 Donkey 
anti-Mouse 
Life Technologies A-21202 1:200 
Alexa 488 Donkey 
anti-Rabbit 
Life Technologies A-21206 1:200 
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APPENDIX C 
TABLE 3: LEICA TCS SP5 AOBS SPECTRAL CONFOCAL SYSTEM LASER POWER 
AND PMT SETTINGS 
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Laser Power (%) PMT spectral range 
(nm) 
UV 12.5 430-550 
488 20 500-600 
633 20 650-750 
 
